Business Context and Reporting Period
This Form 8-K was filed by ReShape Lifesciences Inc. (Note: The request metadata listed "Vyome Holdings, Inc," but the filing text identifies the registrant as ReShape Lifesciences Inc.) on April 20, 2023. The report details the entry into a Material Definitive Agreement for a registered direct offering and a concurrent private placement. The offering closed on April 24, 2023.
Key Financial Metrics and Transaction Details
- Gross Proceeds: Approximately $2.46 million before deducting placement agent fees and offering expenses.
- Securities Issued:
- 291,395 shares of Common Stock at $3.07 per share.
- 509,300 Pre-funded Warrants at $3.069 per share.
- 800,695 Common Warrants issued in a concurrent private placement.
- Placement Agent Fees: Maxim Group LLC received a cash fee of 7.0% of gross proceeds, expense reimbursement, and warrants to purchase 40,035 shares (5.0% of the aggregate offering) at an exercise price of $3.38 per share.
- Warrant Amendments: Existing warrants held by the Investor for 164,656 shares were amended, reducing the exercise price from $15.00 to $3.07 per share.
Material Changes and Transaction Terms
The primary material change is the capital raise and the associated dilution from the issuance of new shares and warrants. Key terms include:
- Common Warrants: Exercise price of $3.07, exercisable immediately, expiring 5.5 years from issuance. Subject to a 4.99% beneficial ownership limitation.
- Pre-funded Warrants: Exercise price of $0.001 per share.
- Adjustments: Exercise prices and share counts are subject to adjustment for stock dividends, splits, or fundamental transactions.
Guidance, Outlook, and Risks
The filing does not provide specific financial guidance, revenue outlook, or management commentary regarding future operational performance. The document focuses strictly on the terms of the securities purchase agreement. Risks associated with the transaction include:
- Dilution: The issuance of new shares and warrants will dilute existing shareholders.
- Unregistered Securities: The Common Warrants were offered under Section 4(a)(2) and Rule 506(b) exemptions and are not registered under the Securities Act of 1933.
- Ownership Caps: Holders cannot exercise warrants if it would cause their beneficial ownership to exceed 4.99% of outstanding shares.
Investor Verification Checklist
- Verify the net proceeds after deducting the 7.0% placement fee and offering expenses.
- Confirm the total number of shares outstanding post-offering to assess the dilution impact of the 291,395 new shares and potential warrant exercises.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for covenants or restrictions not summarized in the 8-K.
- Check the company's cash position in the most recent 10-Q or 10-K to understand the liquidity impact of the $2.46 million raise.